Freenome, a South San Francisco, CA-based biotech company, acquired Oncimmune Ltd, a Nottingham, UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.
The amount of the deal was not disclosed.
Led by Dr. Adam M. Hill, CEO, Oncimmune is a subsidiary of Oncimmune Holdings plc, a cancer immune-profiling company, with an advanced autoantibody profiling technology and database. EarlyCDT Lung is Oncimmune Ltd’s commercialized CE-IVD marked lung blood test and detects elevated levels of autoantibodies generated by the body’s immune system of patients in the earliest stages of lung cancer. The test has impacted the clinical journey of more than 200,000 people at high risk for lung cancer and those with indeterminate pulmonary nodules (IPN).
The acquisition of Oncimmune Ltd provides Freenome with clinical and commercial resources to complement Freenome’s frontline screening efforts. Oncimmune Ltd’s pipeline of autoantibody targets for other cancer indications will augment Freenome’s multiomics platform with additional non-tumor-derived signals to capture a more comprehensive view of the tumor microenvironment.
Led by Mike Nolan, CEO, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages using a standard blood draw. The company is completing the FDA verification and validation studies for its colorectal cancer screening test through the PREEMPT CRC trial. In parallel, Freenome has applied its expertise in cancer detection and machine learning to real-world data to develop population health solutions for payers and providers to complement its blood tests and support the entire patient’s care journey.
The company joins seven of the top 15 global pharma companies in leveraging Oncimmune’s autoantibody discovery platform, ImmunoINSIGHTS, based in Dortmund, Germany, a tool used to uncover meaningful insights and biomarkers for cancer and other diseases.
The Nottingham office will continue its operations. Oncimmune Ltd employees join the Freenome team effective May 20, 2023.
FinSMEs
22/05/2023